Key Highlights
- Haystack Oncology, a subsidiary of Quest Diagnostics, partners with TriSalus Life Sciences to enhance clinical development of SD-101, an investigational cancer treatment.
- The collaboration aims to improve therapeutic responses in liver and pancreatic cancers using Haystack MRD™ technology for precise detection of tumor DNA.
- SD-101, delivered through unique PEDD™ technology, targets hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma in clinical trials.
Source: PR Newswire
Notable Quotes
- “Haystack MRD’s sensitivity enables clinical investigators to closely follow molecular response and measure early evidence of treatment efficacy,” – Dan Edelstein, Vice President and General Manager at Haystack Oncology
- “We are thrilled to work with Haystack in pursuit of our mission to develop better therapeutic options for patients with liver and pancreatic tumors,” – Steven Katz, MD, Chief Medical Officer at TriSalus Life Sciences
SoH's Take
This collaboration between Haystack Oncology and TriSalus Life Sciences represents a significant leap in the fight against some of the most challenging forms of cancer. Leveraging the cutting-edge Haystack MRD technology to detect circulating tumor DNA, this partnership underscores the growing importance of precision medicine in oncology. The unique approach of using SD-101, coupled with Pressure-Enabled Drug Delivery™, shows promise in addressing the historically difficult task of treating liver and pancreatic tumors. The combination of advanced molecular insights and innovative drug delivery methods could herald a new era in cancer therapy, offering hope to patients and potentially setting new standards in treatment efficacy and patient care.
